uniQure prices $300 million public offering at $47.50 per share

uniQure N.V. (NASDAQ: QURE) announced it priced its public offering of 5,789,473 ordinary shares at $47.50 per share, along with pre-funded warrants to purchase 526,316 ordinary shares at the same price minus a $0.0001 exercise price.

The gene therapy company expects to raise approximately $300 million in gross proceeds before underwriting discounts and expenses. The offering is scheduled to close on or about September 29, 2025, subject to customary closing conditions.

uniQure granted underwriters a 30-day option to purchase up to 947,368 additional ordinary shares at the public offering price, less underwriting discounts and commissions.

Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen serve as bookrunning managers for the offering, while H.C. Wainwright & Co. acts as lead manager.

The securities are being offered under uniQure's shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 7, 2025. A preliminary prospectus supplement was filed on September 24, 2025.

uniQure, based in Lexington, Massachusetts and Amsterdam, develops gene therapies for patients with severe medical conditions. The company has an approved gene therapy for hemophilia B and is advancing treatments for Huntington's disease, refractory temporal lobe epilepsy, ALS and Fabry disease.

You May Also Be Interested In

• Viking Therapeutics raises $575M through stock and note offerings
• AtlasClear insiders buy 815,000 shares for roughly $162,500
• BRC Group to acquire Sangoma Technologies for ~$204M